Paxman AB (PAX) Fair Value & Analysis
Healthcare · SE · Market cap 1.3B SEK
Fair value as of: Jun 24, 2026
From 7 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from kr 6.03 to kr 21.75 (+260.7%) since Jun 23, 2026. Share price −12.2% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 44.45 – kr 84.66 · fair‑value band kr 17.47 – kr 26.03 · the kr 49.30 price screens above the kr 21.75 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Paxman AB (PAX) currently trades at kr 49.30, while our model-based Fair Value estimate is kr 21.75 — implying the stock looks roughly 55.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Paxman AB generated revenue of 345M SEK at a net margin of -3.3%. Revenue grew 30.7% year over year. It earns a return on equity of -3.3%. The balance sheet holds a net cash position of 108M SEK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Paxman AB reported revenue of kr 313M in FY2025 versus kr 96.2M in FY2021, a compound +34.3%/yr. Reported net income was −kr 16.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 82.40 MXN | -95% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Paxman AB (PAX) undervalued?
What is the fair value of PAX?
What is the quality score of PAX?
What is the revenue of Paxman AB (PAX)?
What is the net profit margin of PAX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.